A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Inclusion Criteria:

• Previously treated or treatment naïve patients with a documented diagnosis of wAMDin the study eye, with onset of disease that began at any time prior to theScreening Visit.

• Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellenequivalent) in the study eye at the Screening Visit and on Baseline (Day 1).

• For previously-treated subjects, must have been treated with at least 2 anti-VEGFIVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab,or faricimab) in the previous 6 months for wAMD per standard of care in the studyeye prior to the Screening Visit.

Exclusion Criteria:

• Subfoveal fibrosis, atrophy, or scarring in the center subfield.

• BCVA using ETDRS charts <20 letters (20/400 Snellen equivalent) in the fellow eye.